Rheumatic diseases clinics of North America Journal Impact Factor & Information

Publisher: WB Saunders

Current impact factor: 2.69

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.692
2013 Impact Factor 1.736
2012 Impact Factor 2.096
2011 Impact Factor 3.02
2010 Impact Factor 3.018
2009 Impact Factor 2.594
2008 Impact Factor 1.77
2007 Impact Factor 2.16
2006 Impact Factor 2.568
2005 Impact Factor 2.842
2004 Impact Factor 2.146
2003 Impact Factor 2.776
2002 Impact Factor 3.314
2001 Impact Factor 2.156
2000 Impact Factor 2.257
1999 Impact Factor 2.06
1998 Impact Factor 2.175
1997 Impact Factor 1.99
1996 Impact Factor 2.295
1995 Impact Factor 2.444
1994 Impact Factor 2.225
1993 Impact Factor 1.331
1992 Impact Factor 1.221

Impact factor over time

Impact factor

Additional details

5-year impact 2.47
Cited half-life 8.20
Immediacy index 0.34
Eigenfactor 0.00
Article influence 0.83
Other titles Rheumatic diseases clinics of North America (Online), Rheumatic diseases clinics of North America, Rheumatic disease clinics of North America, Rheumatic disease clinics
ISSN 1558-3163
OCLC 60626445
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

WB Saunders

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Pre-print allowed on any website or open access repository
    • Voluntary deposit by author of authors post-print allowed on institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
    • Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PubMed Central after 12 months
    • Authors who are required to deposit in subject-based repositories may also use Sponsorship Option
    • Publisher last reviewed on 03/07/2015
    • 'WB Saunders' is an imprint of 'Elsevier'
  • Classification

Publications in this journal

  • Rheumatic diseases clinics of North America 10/2015; 41(4):xi. DOI:10.1016/j.rdc.2015.09.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a strong familial component to psoriatic disease as well as a complex array of genetic, immunologic, and environmental factors. The dominant genetic effect is located on chromosome 6p21.3 within the major histocompatibility complex region, accounting for one-third of genetic contribution. Genome-wide association studies (GWAS) identified additional genes, including skin barrier function, innate immune response, and adaptive immune response genes. To better understand disease susceptibility and progression requires replication in larger cohorts, fine-mapping efforts, new technologies, and functional studies of genetic variants, gene-gene interactions and gene-environmental interactions. New technologies available include next-generation sequencing, copy number variation analysis, and epigenetics.
    Rheumatic diseases clinics of North America 10/2015; 41(4):623-642. DOI:10.1016/j.rdc.2015.07.002

  • Rheumatic diseases clinics of North America 10/2015; 41(4):xiii-xiv. DOI:10.1016/j.rdc.2015.09.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Skin psoriasis is a major risk factor for the development of psoriatic arthritis. Recent studies have shown that delayed diagnosis is associated with long-term adverse outcomes. Screening questionnaires have revealed a potential burden of undiagnosed disease. Lifestyle factors and genetic and soluble biomarkers have come under scrutiny as risk factors. Imaging modalities may have an important role in detecting early change. With more effective treatments, it may be possible to prevent significant joint damage and associated disability. However, the precise nature of accurate and cost-effective screening strategies remains to be determined.
    Rheumatic diseases clinics of North America 10/2015; 41(4):615-622. DOI:10.1016/j.rdc.2015.07.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by joint and entheseal inflammation with a prevalence of 0.05% to 0.25% of the population and 6% to 41% of patients with psoriasis. PsA is a highly heterogeneous inflammatory arthritis. In this review, current knowledge is discussed regarding the epidemiology of PsA, including disease manifestations, classification criteria for adult and juvenile PsA, methods for recognizing early PsA, including use of screening tools and knowledge of risk factors for PsA, and medical comorbidities associated with PsA.
    Rheumatic diseases clinics of North America 10/2015; 41(4):545-568. DOI:10.1016/j.rdc.2015.07.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although early reports suggested psoriatic arthritis was, with the exception of arthritis mutilans, a relatively mild arthritis, later studies have challenged this view. The burden of skin disease adds to disability and impaired quality of life. Patients in secondary care manifest increased morbidity and mortality, mainly owing to cardiovascular disease. A subset of patients, primarily men with oligoarticular disease, demonstrates low levels of joint involvement without disability. The socioeconomic impact of the disease is significant. We require more information on the impact of early diagnosis and treatment on outcome, according to phenotype, to guide policy.
    Rheumatic diseases clinics of North America 10/2015; 41(4):581-591. DOI:10.1016/j.rdc.2015.07.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiologic studies have shown that, in patients with psoriatic arthritis (PsA), associated comorbidities may occur more frequently than expected. This article discusses related comorbidities in patients with PsA. Identifying these comorbidities may affect the management and treatment decisions for these patients to ensure an optimal clinical outcome. All health care providers caring for patients with PsA should be aware of the relevant comorbidities and should have an understanding of how these comorbidities affect management. The common comorbidities include cardiovascular disease, metabolic syndrome, obesity, diabetes, fatty liver disease, inflammatory bowel disease, ophthalmic disease, kidney disease, osteoporosis, depression, and anxiety.
    Rheumatic diseases clinics of North America 10/2015; 41(4):677-698. DOI:10.1016/j.rdc.2015.07.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biologic medications, therapeutic proteins that inhibit or modulate proinflammatory immune cells and cytokines, have significantly altered clinicians' ability to effectively treat psoriatic arthritis (PsA). The first widely used biologics have been those targeting tumor necrosis factor alpha. Five agents (etanercept, infliximab, adalimumab, golimumab, and certolizumab) have shown significant benefit in all clinical domains of PsA as well as inhibiting progressive joint destruction. Treatment strategies such as treating PsA early in the disease course, treating to target and tight control, use of background methotrexate to reduce immunogenicity, and various cost-saving strategies are all being tested with biologic medicines for PsA.
    Rheumatic diseases clinics of North America 10/2015; 41(4):723-738. DOI:10.1016/j.rdc.2015.07.010
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the last decade, there have been significant advances in outcome measure research in psoriatic arthritis (PsA). In this article, the outcome measures for disease activity in individual key domains of PsA are reviewed, followed by the key patient-reported outcome measures of function, quality of life, fatigue, and a new measure for disease impact, the psoriatic arthritis impact of disease. New research into composite measures of psoriatic disease is summarized, including response measures and proposed cutoff points for disease activity. Finally, the key future issues in outcome measurement in PsA are addressed.
    Rheumatic diseases clinics of North America 10/2015; 41(4):699-710. DOI:10.1016/j.rdc.2015.07.009

  • Rheumatic diseases clinics of North America 08/2015; 41(3):xiii. DOI:10.1016/j.rdc.2015.06.002

  • Rheumatic diseases clinics of North America 08/2015; 41(3):xv-xvi. DOI:10.1016/j.rdc.2015.06.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung disease commonly occurs in connective tissue diseases (CTD) and is an important cause of morbidity and mortality. Imaging is central to the evaluation of CTD-associated pulmonary complications. In this article, a general discussion of radiologic considerations is followed by a description of the pulmonary appearances in individual CTDs, and the imaging appearances of acute and nonacute pulmonary complications. The contribution of imaging to monitoring disease, evaluating treatment response, and prognostication is reviewed. Finally, we address the role of imaging in the challenging multidisciplinary evaluation of interstitial lung disease where there is an underlying suspicion of an undiagnosed CTD. Copyright © 2015 Elsevier Inc. All rights reserved.
    Rheumatic diseases clinics of North America 05/2015; 41(2):167-196. DOI:10.1016/j.rdc.2014.12.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: The major manifestations of antiphospholipid syndrome (APS) are caused by thrombosis within the venous or arterial vasculature, whereas the vascular lesions in systemic vasculitis result from an inflammatory infiltrate in the vessel wall. There is an association between vascular thrombosis and inflammation, however, as vasculitis can occur in APS and thromboembolic complications are seen in systemic vasculitis. Although differentiating between vasculitis and antiphospholipid-associated thrombosis can be difficult, it may be crucial to do so given the different therapeutic implications for immunosuppression or anticoagulation. This article explores the relationship between thrombosis and inflammation as it relates to APS and systemic vasculitis.
    Rheumatic diseases clinics of North America 02/2015; 41(1):109-123. DOI:10.1016/j.rdc.2014.09.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article provides an update on the diagnosis and management of the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, granulomatosis with polyangiitis (formerly Wegener), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss). Focus is on new schemes of classification and the importance of ANCAs in the diagnosis and prognosis of these systemic vasculitides. Current therapeutic strategies consisting of glucocorticoids in conjunction with conventional or biologic agents for both induction of remission and remission maintenance are outlined. Future research directions include investigation of the optimal duration and frequency of maintenance therapy and development of targeted therapeutic agents.
    Rheumatic diseases clinics of North America 02/2015; 41(1):1-19. DOI:10.1016/j.rdc.2014.09.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary angiitis of the central nervous system (PACNS) is a rare disease, although it is increasingly recognized both in adults and children. Little is known about pathogenesis, but efforts at classification into subtypes are being made, and the distinction of PACNS from reversible cerebral vasoconstriction syndrome has been a major advance. The prognosis for improvement, or at least stabilization, of neurologic function is good with prompt and aggressive treatment, but the diagnosis continues to be challenging. Refinement of treatment strategies is needed. Multicenter collaboration may be crucial to make additional progress via randomized trials.
    Rheumatic diseases clinics of North America 02/2015; 41(1):47-62. DOI:10.1016/j.rdc.2014.09.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: The need to distinguish true primary systemic vasculitis from its multiple potential mimickers is one of the most challenging diagnostic conundrums in clinical medicine. This article reviews 9 challenging vasculitis mimickers: fibromuscular dysplasia, calciphylaxis, segmental arterial mediolysis, antiphospholipid syndrome, hypereosinophilic syndrome, lymphomatoid granulomatosis, malignant atrophic papulosis, livedoid vasculopathy, and immunoglobulin G4-related disease.
    Rheumatic diseases clinics of North America 02/2015; 41(1):141-160. DOI:10.1016/j.rdc.2014.09.011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cogan and Behcet syndromes are considered large vessel vasculitides. Both are rare diseases, with varied clinical manifestations affecting multiple organ systems. Although both have hallmark symptoms (ocular and vestibuloauditory inflammation in Cogan syndrome and aphthous ulcers in Behcet syndrome), neither has confirmatory diagnostic testing. Delayed diagnosis can result in poor outcomes. In both syndromes, large vessel arterial inflammation may result in severe morbidity and mortality. Treatment strategies in both syndromes vary based on organ system involvement and severity of manifestations. In this article, the epidemiology, proposed pathogenesis, manifestations, and the most current treatment paradigms for these syndromes are reviewed.
    Rheumatic diseases clinics of North America 02/2015; 41(1):75-91. DOI:10.1016/j.rdc.2014.09.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Small vessel vasculitis in the skin manifests with palpable purpura on the lower extremities. This clinical presentation prompts a complete physical examination, history, and review of systems, as well as biopsies for routine processing and direct immunofluorescence to confirm the diagnosis. The presence of vasculitis in other organs, associated underlying conditions, and the severity of cutaneous manifestations dictate management. The majority of cases are self-limited, and overall the prognosis is favorable. Still, a subset of patients can have serious complications and chronic or recurrent disease.
    Rheumatic diseases clinics of North America 02/2015; 41(1):21-32. DOI:10.1016/j.rdc.2014.09.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cryoglobulins are immunoglobulins that precipitate at temperatures less than 37°C. They occur secondary to infectious, autoimmune, and malignant processes. In the Brouet classification, type I cryoglobulinemia is caused by hyperviscosity, whereas type II and III manifestations are caused by vasculitis in target organs (primarily skin, peripheral nerves, and kidney). New classification criteria were recently proposed that may help with study and treatment of cryoglobulinemic vasculitis (CryoVas). Hepatitis C virus is the most common cause of CryoVas and treatment with antivirals can be curative in mild cases, whereas rituximab is highly effective in treating active vasculitis in more severe cases.
    Rheumatic diseases clinics of North America 02/2015; 41(1):93-108. DOI:10.1016/j.rdc.2014.09.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Polyarteritis nodosa (PAN) is a systemic disease, but variants are cutaneous PAN and single-organ disease. Histologic confirmation of vasculitis in medium-sized arteries is desirable, and biopsies should be obtained from the symptomatic and least invasive sites. Angiography can show multiple microaneurysms in the viscera. Treatment includes high-dose corticosteroids, which are combined with immunosuppressive agents when internal organs are involved and with life-threatening disease. Once remission is achieved, maintenance agents are initiated. PAN is becoming a rare disease. International collaborative efforts are under way to establish better diagnostic and classification for all vasculitides, including PAN.
    Rheumatic diseases clinics of North America 02/2015; 41(1):33-46. DOI:10.1016/j.rdc.2014.09.005